Strategic Vision: A Global Pharma Company
Q4 FY2022 Snapshot
Sales (INR mn, YoY Growth)
India,
13,511
Total
38,645, 2.8%
North
America,
14,162
Important developments
Commercial
Lupin Completes Acquisition of Brands from Anglo-French
Completed Southern Cross acquisition in Australia
Lupin and Yabao Announce Strategic Partnership in China
Lupin and Axantia Enter into a License, Supply and Technology
Sharing Agreement for Pegfilgrastim in the Middle East and North.
Africa
API, 2,203
ROW, 887 EMEA,
Growth
Markets,
Pipeline
3,810
4,072
Received US FDA approval for :
EBITDA
R&D
INR 2,823 mn
INR 3,442 mn
7.3%
% of Sales
8.9%
% of Sales
➤ Sildenafil for Oral Suspension
Vigabatrin for Oral Solution USP
Arformoterol Tartrate Inhalation Solution
Regulatory
US FDA inspected Tarapur facility
LUPIN
6View entire presentation